These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35853358)

  • 21. CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review.
    Rinaldi V; Bellucci G; Buscarinu MC; Reniè R; Marrone A; Nasello M; Zancan V; Nistri R; Palumbo R; Salerno A; Salvetti M; Ristori G
    Front Neurol; 2022; 13():1018785. PubMed ID: 36530641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica.
    Ciotti JR; Eby NS; Wu GF; Naismith RT; Chahin S; Cross AH
    Mult Scler Relat Disord; 2020 Oct; 45():102399. PubMed ID: 32702642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicentric clinical and epidemiological comparison of neuromyelitis optica spectrum disorder with multiple sclerosis from India.
    Gupta S; Rehani V; Acharya R; Purohit P; Anadure R; Ahmad F; Soni R; Gupta A; Hiremath R
    Mult Scler Relat Disord; 2021 Jan; 47():102616. PubMed ID: 33166808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis.
    Nepal G; Kharel S; Coghlan MA; Rayamajhi P; Ojha R
    J Neuroimmunol; 2022 Mar; 364():577812. PubMed ID: 35063726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical course of neuromyelitis optica (Devic's syndrome).
    Wingerchuk DM; Hogancamp WF; O'Brien PC; Weinshenker BG
    Neurology; 1999 Sep; 53(5):1107-14. PubMed ID: 10496275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
    Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
    Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated Adenosine Deaminase Levels in the Cerebrospinal Fluid in Immune Checkpoint Inhibitor-induced Autoimmune Encephalitis.
    Fujiwara S; Mimura N; Yoshimura H; Fujimoto D; Ito M; Mori R; Ito J; Tomii K; Kawamoto M; Kohara N
    Intern Med; 2019 Oct; 58(19):2871-2874. PubMed ID: 31243206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Could Galectin-3 be a key player in the etiology of neuromyelitis optica spectrum disorder?
    Ramakrishnan P
    Med Hypotheses; 2021 Jan; 146():110450. PubMed ID: 33309338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK.
    O'Connell K; Hamilton-Shield A; Woodhall M; Messina S; Mariano R; Waters P; Ramdas S; Leite MI; Palace J
    J Neurol Neurosurg Psychiatry; 2020 Oct; 91(10):1126-1128. PubMed ID: 32576617
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders.
    Tzartos JS; Stergiou C; Kilidireas K; Zisimopoulou P; Thomaidis T; Tzartos SJ
    PLoS One; 2013; 8(9):e74773. PubMed ID: 24086369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.
    Lin L; Wu Y; Hang H; Lu J; Ding Y
    Front Immunol; 2022; 13():853891. PubMed ID: 35898513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Central nervous system complications associated with immune checkpoint inhibitors.
    Vogrig A; Muñiz-Castrillo S; Joubert B; Picard G; Rogemond V; Marchal C; Chiappa AM; Chanson E; Skowron F; Leblanc A; Ducray F; Honnorat J
    J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):772-778. PubMed ID: 32312871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuromyelitis optica spectrum disorders in South of Tunisia: A rare entity with low seroprevalence of anti-aquaporin 4 autoantibodies.
    Mejdoub S; Feki S; Dammak M; Farhat N; Hdiji O; Boukthir S; Hachicha H; Mhiri C; Masmoudi H
    Rev Neurol (Paris); 2020 May; 176(4):261-267. PubMed ID: 31668529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders.
    Banwell B; Tenembaum S; Lennon VA; Ursell E; Kennedy J; Bar-Or A; Weinshenker BG; Lucchinetti CF; Pittock SJ
    Neurology; 2008 Jan; 70(5):344-52. PubMed ID: 18094334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort.
    Edgar Patricio CD; Eleanor THG; Francisco José CZ; Gabriela ACM; Hyland AO; Fernando GL; María TA; Beatriz N; Marcos SD; Alfredo GPW
    Mult Scler Relat Disord; 2020 Sep; 44():102208. PubMed ID: 32562910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic options in neuromyelitis optica spectrum disorders.
    Kitley J; Palace J
    Expert Rev Neurother; 2016; 16(3):319-29. PubMed ID: 26840802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.
    Ramanathan S; Mohammad S; Tantsis E; Nguyen TK; Merheb V; Fung VSC; White OB; Broadley S; Lechner-Scott J; Vucic S; Henderson APD; Barnett MH; Reddel SW; Brilot F; Dale RC;
    J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):127-137. PubMed ID: 29142145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-NMDAR encephalitis associated with relapsing optic neuritis].
    Belova AN; Grygorieva VN; Rasteryaeva MV; Ruina EA; Belova EM; Solovieva VS; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(6):105-113. PubMed ID: 32678556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent Optic Neuritis as the Initial Symptom in Demyelinating Diseases.
    Falcão-Gonçalves AB; Bichuetti DB; de Oliveira EML
    J Clin Neurol; 2018 Jul; 14(3):351-358. PubMed ID: 29856159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management.
    Sechi E; Cacciaguerra L; Chen JJ; Mariotto S; Fadda G; Dinoto A; Lopez-Chiriboga AS; Pittock SJ; Flanagan EP
    Front Neurol; 2022; 13():885218. PubMed ID: 35785363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.